INDEMNIFICATION AGREEMENTIndemnification Agreement • October 2nd, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledOctober 2nd, 2018 Company Industry JurisdictionTHIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of April 6, 2018 between Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and John DeYoung (“Indemnitee”).
ALLOGENE THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20__ Debt SecuritiesIndenture • November 2nd, 2022 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 2nd, 2022 Company Industry JurisdictionINDENTURE, dated as of [•], 20__, among Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
ALLOGENE THERAPEUTICS, INC. AND _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • March 14th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 14th, 2024 Company Industry JurisdictionTHIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
Allogene Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • June 4th, 2020 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 4th, 2020 Company Industry JurisdictionAllogene Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 11,702,128 shares of the Company’s common stock, par value $0.001 per share (“Stock”, and such shares, the “Firm Shares”) and, at the election of the Underwriters, up to 1,755,319 additional shares (the “Optional Shares”) of Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
ALLOGENE THERAPEUTICS, INC. AND _____________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________Common Stock Warrant Agreement • November 2nd, 2022 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 2nd, 2022 Company Industry JurisdictionTHIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
ALLOGENE THERAPEUTICS, INC. AND _____________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • March 14th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 14th, 2024 Company Industry JurisdictionTHIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
ALLOGENE THERAPEUTICS, INC. AND _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________Preferred Stock Warrant Agreement • November 2nd, 2022 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 2nd, 2022 Company Industry JurisdictionTHIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
INDEMNITY AGREEMENTIndemnity Agreement • October 2nd, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledOctober 2nd, 2018 Company Industry JurisdictionTHIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between ALLOGENE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • August 10th, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledAugust 10th, 2018 Company Industry JurisdictionTHIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of April 6, 2018 by and among Allogene Therapeutics, Inc. a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
ALLOGENE THERAPEUTICS, INC. AND _____________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF __________Securities Warrant Agreement • November 2nd, 2022 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 2nd, 2022 Company Industry JurisdictionTHIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
ALLOGENE THERAPEUTICS, INC. $250,000,000 COMMON STOCK SALES AGREEMENTAllogene Therapeutics, Inc. • November 5th, 2019 • Biological products, (no disgnostic substances) • New York
Company FiledNovember 5th, 2019 Industry JurisdictionAllogene Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ALLOGENE THERAPEUTICS, INC. Shares of Common Stock ($0.001 par value) AMENDMENT NO. 1 TO THE SALES AGREEMENTCommon Stock Sales Agreement • November 2nd, 2022 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 2nd, 2022 Company Industry JurisdictionReference is made to the Sales Agreement, dated November 5, 2019 (the “Agreement”), by and between Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (the “Agent”). The Company and the Agent (collectively, the “Parties”) wish to amend the Agreement, pursuant to Section 15 of the Agreement, to allow for the issuance and sale of Placement Shares under the Agreement pursuant to a new Registration Statement (as defined below) (this “Amendment”). The Parties therefore hereby agree as follows:
BRITANNIA POINTE GRAND BUSINESS PARK LEASELease • August 10th, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledAugust 10th, 2018 Company Industry JurisdictionThis Lease (the “Lease”), dated as of the Execution Date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between BRITANNIA POINTE GRAND LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and ALLOGENE THERAPEUTICS, INC., a Delaware corporation (“Tenant”). Landlord and Tenant may each be referred to in this Lease individually as a “Party” and collectively as the “Parties.”
Re: Employment Letter of Agreement (“Agreement”)Invention Assignment Agreement • September 14th, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledSeptember 14th, 2018 Company Industry JurisdictionAllogene Therapeutics, Inc. (“Allogene” or the “Company”) is pleased to offer you employment on the following terms and conditions.
August 11, 2023 Earl Douglas Re: Employment Letter of Agreement (“Agreement”) Dear Earl,Restricted Stock Unit Agreement • November 2nd, 2023 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledNovember 2nd, 2023 Company Industry JurisdictionAllogene Therapeutics, Inc. (“Allogene” or the “Company”) is pleased to offer you employment on the following terms and conditions.
CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A...License Agreement • May 7th, 2019 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 7th, 2019 Company Industry JurisdictionThis License Agreement (the “Agreement”) is entered into as of March 8, 2019 (the “Effective Date”), by and among Allogene Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 210 East Grand Avenue, South San Francisco, California, 94080 (“Allogene”) and Cellectis SA, a corporation organized and existing under the laws of France and having a place of business at 8 rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Allogene and Cellectis may each be referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 14th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 14th, 2024 Company Industry JurisdictionThis Amended and Restated Collaboration and License Agreement (the “Agreement”), effective as of [***] (the “Restatement Effective Date”), is made by and between Allogene Therapeutics, Inc., a Delaware corporation with its principal place of business at 210 East Grand Ave., South San Francisco, CA 94080 (“Allogene”), and Notch Therapeutics (Canada) Inc., having an address at 300-2233 Columbia St, Vancouver, BC V5Y 0M6 (“Notch”). Allogene and Notch are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ASSET CONTRIBUTION AGREEMENT BY AND BETWEEN PFIZER INC. AND ALLOGENE THERAPEUTICS, INC. Dated as of April 2, 2018Asset Contribution Agreement • October 2nd, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledOctober 2nd, 2018 Company Industry JurisdictionThis Asset Contribution Agreement (this “Agreement”) is entered into as of April 2, 2018 (the “Effective Date”), by and between Pfizer Inc., a Delaware corporation (“Pfizer”), and Allogene Therapeutics, Inc., a Delaware corporation (“NewCo”).
CONSULTING AGREEMENTConsulting Agreement • May 3rd, 2023 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledMay 3rd, 2023 Company Industry JurisdictionTHIS CONSULTING AGREEMENT (this “Agreement”), effective as of April 29, 2023 (“Effective Date”), is by and between Alison Moore, Ph.D., having an address at 5 Hill Ave., San Carlos, CA 94070 (“Consultant”) and Allogene Therapeutics, Inc. having an address at 210 East Grand Avenue, South San Francisco, CA 94080 (“Allogene”).
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • August 7th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledAugust 7th, 2024 Company IndustryAGREEMENT (this “Amendment”), is made and effective as of May 17, 2024 (the “Amendment Effective Date”), is made by and between Allogene Therapeutics, Inc., a Delaware corporation with its principal place of business at 210 East Grand Ave., South San Francisco, CA 94080 (“Allogene”), and Notch Therapeutics (Canada) Inc., having an address at 300-2233 Columbia St, Vancouver, BC V5Y 0M6 (“Notch”). Allogene and Notch are sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties.” Capitalized terms not defined herein shall have the meanings ascribed to them in the License Agreement.
ALLOGENE THERAPEUTICS, INC. Shares of Common Stock ($0.001 par value) AMENDMENT NO. 2 TO THE SALES AGREEMENTAllogene Therapeutics, Inc. • November 2nd, 2023 • Biological products, (no disgnostic substances)
Company FiledNovember 2nd, 2023 IndustryReference is made to the Sales Agreement, dated November 5, 2019, as amended by Amendment No.1 to the Sales Agreement (the “Amendment No. 1”), dated November 2, 2022 (as amended, the “Agreement”) by and between Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (the “Agent”). The Company and the Agent (collectively, the “Parties”) wish to amend the Agreement, pursuant to Section 15 of the Agreement, to remove the specified aggregate dollar amount of Placement Shares that may be issued and sold from time to time under the Agreement (this “Amendment”). The Parties therefore hereby agree as follows:
Allogene Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • May 14th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 14th, 2024 Company IndustryAllogene Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to Goldman Sachs & Co. LLC (the “Underwriter”) an aggregate of 36,896,551 shares of the Company’s common stock, par value $0.001 per share (“Stock”, and such shares, the “Shares”).
STRATEGIC COLLABORATION AGREEMENT between FORESIGHT DIAGNOSTICS, INC. and ALLOGENE THERAPEUTICS, INC. Dated as of January 3, 2024 STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • March 14th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 14th, 2024 Company IndustryThis Strategic Collaboration Agreement (this “Agreement”) is effective as of January 3, 2024 (the “Effective Date”) by and between Foresight Diagnostics, Inc., having a principal place of business at 2865 Wilderness Place, Boulder, CO 80301 (“Foresight”), and Allogene Therapeutics, Inc., having a principal place of business at 210 East Grand Avenue, South San Francisco, CA 94080 (“Company”). Foresight and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT AND SETTLEMENT AGREEMENTAnd Settlement Agreement • August 7th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledAugust 7th, 2024 Company IndustryTHIS AMENDMENT AND SETTLEMENT AGREEMENT (this “Amendment”) is made and entered into by and between Les Laboratoires Servier, a société par actions simplifiée incorporated under the laws of France having a principal place of business at 50 rue Carnot, 92150 Suresnes, France (“LLS”) and Institut de Recherches Internationales Servier, a société à responsabilité limitée incorporated under the laws of France having its principal place of business at 22 Route 128, 91190 Gif-sur-Yvette, France (“IRIS”) (LLS and IRIS being together referred to as “Servier”), and Allogene Therapeutics, Inc., a Delaware corporation having its principal place of business at 210 East Grand Avenue, South San Francisco, CA 94080, USA (“Allogene”) with effective date as of April 9, 2024 (the “Amendment Date”). Each of Servier and Allogene are referred to herein as a “Party” and collectively as the “Parties”.
AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENTShareholders’ Agreement • August 7th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledAugust 7th, 2024 Company Industry JurisdictionEach of the parties to this Agreement is referred to herein individually as a “Party” and collectively as the “Parties”. Each of Allogene and [***HBP***] is referred to herein as an “Shareholder” and collectively as the “Shareholders”. Capitalized terms used herein without definition have the meanings ascribed to them in the Share Exchange Agreement or the Share Distribution Agreement, as applicable.
SHARE PURCHASE AGREEMENTShare Purchase Agreement • February 25th, 2021 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledFebruary 25th, 2021 Company Industry Jurisdiction1Organization, Standing and Qualification. The Company is duly incorporated or organized, validly existing and in good standing (or equivalent status in the relevant jurisdiction) under the Laws of the jurisdiction of its incorporation or organization. The Company has all requisite capacity, power and authority to own and operate its properties and to carry on its business as now conducted and as proposed to be conducted, and is duly qualified to transact business in each jurisdiction in which it conducts and proposes to conduct business.
TRANSITION SERVICES AGREEMENTTransition Services Agreement • September 14th, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledSeptember 14th, 2018 Company Industry JurisdictionThis TRANSITION SERVICES AGREEMENT (this “Agreement”) is made and entered into as of the 6th day of April, 2018 (the “Effective Date”) between Pfizer, Inc., a Delaware corporation (“Pfizer”), and Allogene Therapeutics, Inc., a Delaware corporation (“NewCo”) (each, a “Party” and together, the “Parties”).
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 7th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledAugust 7th, 2024 Company IndustryThis First Amendment to Exclusive License Agreement (“Amendment”), effective as of May 24, 2024, (the “Amendment Effective Date”) amends the Exclusive License Agreement dated December 14, 2020 (the “License Agreement”) between Allogene Therapeutics, Inc. (“Allogene”) and Allogene Overland BioPharm (PRC) Co., Limited (“AOB PRC” or “Licensee”) (collectively the “Parties” and each a “Party”). Capitalized terms not defined herein shall have the meanings ascribed to them in the License Agreement.
FIRST AMENDMENT TO LEASE (310 Utah Avenue)Lease • February 23rd, 2022 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledFebruary 23rd, 2022 Company IndustryThis FIRST AMENDMENT TO LEASE ("First Amendment") is made and entered into as of December 10, 2021, by and between HEALTHPEAK PROPERTIES, INC., a Delaware corporation ("Landlord"), and ALLOGENE THERAPEUTICS, INC., a Delaware corporation ("Tenant").
FIRST AMENDMENT TO LEASE AGREEMENTLease Agreement • November 5th, 2019 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledNovember 5th, 2019 Company IndustryThis FIRST AMENDMENT TO LEASE AGREEMENT (this "Amendment") is entered into as of September 4, 2019, by and between SILICON VALLEY GATEWAY TECHNOLOGY CENTER, LLC, a Delaware limited liability company ("Landlord"), and ALLOGENE THERAPEUTICS, INC., a Delaware corporation ("Tenant").
April 2, 2018 Allogene Therapeutics, Inc.Allogene Therapeutics, Inc. • September 14th, 2018 • Biological products, (no disgnostic substances)
Company FiledSeptember 14th, 2018 Industry
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 25th, 2021 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledFebruary 25th, 2021 Company Industry JurisdictionTHIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is entered into as of December 14, 2020 (the “Effective Date”), by and between ALLOGENE THERAPEUTICS, INC., a Delaware corporation having a place of business at 210 East Grand Avenue, South San Francisco, CA 94080 (“Allogene”) and ALLOGENE OVERLAND BIOPHARM (CY) LIMITED, an exempted company incorporated in the Cayman Islands with limited liability (“Licensee”) (collectively the “Parties” and each a “Party”).
EDGEWATER BUSINESS PARK LEASEEdgewater Business Park • March 8th, 2019 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledMarch 8th, 2019 Company Industry JurisdictionThis Lease (the "Lease"), dated as of the Execution Date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between EDGEWATER LIMITED PARTNERSHIP, a Delaware limited partnership ("Landlord"), and ALLOGENE THERAPEUTICS, INC., a Delaware corporation ("Tenant"). Landlord and Tenant may each be referred to in this Lease individually as a “Party” and collectively as the “Parties.”
ContractShareholders’ Agreement • February 25th, 2021 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledFebruary 25th, 2021 Company Industry Jurisdiction[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
FIRST AMENDMENT TO LEASELease • February 23rd, 2022 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledFebruary 23rd, 2022 Company IndustryThis FIRST AMENDMENT TO LEASE (this "First Amendment") is made and entered into effective as of December 10, 2021 (the "Effective Date"), by and between BRITANNIA POINTE GRAND LIMITED PARTNERSHIP, a Delaware limited partnership ("Landlord"), and ALLOGENE THERAPEUTICS, INC., a Delaware corporation ("Tenant").